Compare Marathon Petroleum Corp (MPC) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marathon Petroleum Corp vs Sanofi SA — how do they compare? Marathon Petroleum Corp trades at $460.5 (market cap $124.20B), while Sanofi SA trades at $40.26 (market cap $96.81B). The key difference: Marathon Petroleum Corp is the larger of the two by market cap, and Sanofi SA pays the higher dividend (6.02%). Which is the better fit depends on your goals — on Pluang, investors hold Marathon Petroleum Corp for 54 Days and Sanofi SA for 94 Days on average.
| MPC | SNY | |
|---|---|---|
Market Cap | $124.20B | $96.81B |
Volume | 1,923,373 | 2,081,815 |
Sector | Energy | Health |
52-Week High | $463.34 | $52.34 |
52-Week Low | $162.63 | $39.51 |
Typical Hold Time | 54 Days | 94 Days |
Enterprise Value | $150.72B | $116.20B |
Dividend Yield | 0.9% | 6.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marathon Petroleum (MPC) trades at $463.34, up 7.17% over 24 hours and near its 52-week high. The stock exhibits strong bullish momentum with consistent earnings beats and robust profitability metrics, including a 47.9% ROE. Recent news highlights refining margin strength amid tight global capacity, though potential diesel export curbs pose a risk. Technical indicators show bullish moving averages but an overbought RSI, with key resistance at $452.
MPC presents a compelling investment case with solid fundamentals, high analyst buy ratings (75.76%), and a consensus price target of $420.30. Upside is driven by elevated refining margins and earnings growth, but risks include regulatory threats to exports and volatile energy markets. The stock's current premium to target suggests cautious optimism amid near-term overbought conditions.
Sanofi (SNY) trades at $40.23, up 1.69% with recent earnings beats and strong revenue growth to $46.72B in 2025. The stock shows bearish technical signals but maintains solid fundamentals with a 22.2 P/E ratio and 72.77% gross margin. Recent expansion of the Regeneron immunology alliance represents significant strategic positioning for future growth beyond Dupixent.
While near-term technical pressure exists, SNY's fundamental strength and pipeline development provide long-term upside potential. Key risks include patent expiration concerns and competitive pressures in the pharmaceutical sector. Analyst consensus leans slightly positive with 44% buy ratings, though institutional sentiment remains cautious given technical indicators.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marathon Petroleum Corp
Marathon Petroleum is an independent refiner with 13 refineries in the midcontinent, West Coast, and Gulf Coast of the United States with total throughput capacity of 2.9 million barrels per day. Its Dickinson, ND, facility produces 184 million gallons a year of renewable diesel. Its Martinez, CA, facility will have the ability to produce 730 million gallons a year of renewable diesel once converted. The firm also owns and operates midstream assets primarily through its listed MLP, MPLX.
Read more on MPC →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
